Market Access Is money the only metric that really matters in UK’s VPAG? I... The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.
News UK follows through on doubling of statutory scheme rate UK pharma firms have reacted angrily to the news that the government has doubled the statutory scheme rebate on the sales of newer drugs to the NHS.
News UK is becoming an 'outlier' for pharma, hitting investment UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.
News Pharma furious as UK Statutory Scheme rebate rate soars The UK pharma sector has reacted with consternation to the government's proposal to raise the Statutory Scheme rate to 32.2% in the last half of 2025.
Oncology On the forefront of healthcare change, turning innovative sc... Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face